AstraZeneca, innovation-driven biopharmaceutical business, to invest approximately $285 million in a new facility for manufacturing of biological medicines in Södertälje, Sweden. Södertälje is currently main Place to AstraZeneca’s largest global tablets and capsules manufacturing facility. Company will combine its expertise in biologics with the well-established culture of operational excellence that exists within the Sweden operations unit.
The new plant will be focused on filling and packaging of protein therapeutics.
The planned investment will, subject to relevant approvals by the local authorities, create between 150 and 250 highly skilled new roles at AstraZeneca by 2019. The $285 million planned investment is the start up of a potential three-part programme to expand AstraZeneca’s biologics manufacturing capabilities. Further investment decisions are expected to be made in the coming years. The new manufacturing facility in Sweden will support the progression of drug candidates across the main therapy areas and be aligned with investments being made in the current biologics manufacturing centres, such as the expansion in Frederick, Maryland, announced in November.
Södertälje is also the location for the headquarters of AstraZeneca’s Nordic-Baltic marketing company, as well as a number of enabling functions. 3,800 roles are currently based here. The medicines delivered from Sweden Operations account for approximately 35% of AstraZeneca’s total sales value. In 2013, AstraZeneca’s exports of medicines from Sweden totaled 39 billion SEK, which accounts for approximately 3.5% of the total Swedish export of goods.
MedImmune is the worldwide biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines.
Subscribe to PharmaTutor News Alerts by Email >>
